Spermosens Operating Income Over Time
| 9R5 Stock | 0 0.01 83.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Spermosens Performance and Spermosens Correlation. Spermosens |
Cross Equities Operating Income Analysis
Compare Spermosens AB and related stocks such as WuXi AppTec, Thermo Fisher Scientific, and Danaher Operating Income Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WX8 | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.8 B | 2 B | 2.6 B | 3.3 B | 4.7 B | 9.7 B | 11.8 B | 11.6 B | 13.4 B | 14 B |
| TN8 | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.5 B | 2.6 B | 3.1 B | 3.8 B | 4.2 B | 7.9 B | 10.2 B | 8.5 B | 7.3 B | 7.7 B | 8.9 B | 6 B |
| DAP | 19.9 M | 2.6 B | 3.2 B | 3.3 B | 3.4 B | 3.5 B | 2.8 B | 3 B | 3.4 B | 3.3 B | 4.2 B | 7.5 B | 8.7 B | 5.2 B | 4.9 B | 4.7 B | 4.9 B |
| DAP | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.3 B | 2.8 B | 3 B | 3.4 B | 3.3 B | 4.2 B | 7.5 B | 8.7 B | 5.2 B | 4.9 B | 5.6 B | 4.7 B |
| SHL | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2 B | 2.3 B | 1.9 B | 2.6 B | 2.9 B | 2.1 B | 2.8 B | 2.8 B | 3.2 B | 2.6 B |
| IX1 | 269.8 M | 269.8 M | 269.8 M | 269.8 M | 269.8 M | 308.1 M | 350.2 M | 413 M | 491.3 M | 552.8 M | 694.5 M | 932 M | 898.8 M | 1.1 B | 1.1 B | 1.3 B | 713.6 M |
| AG8 | 419 M | 419 M | 419 M | 419 M | 525 M | 615 M | 841 M | 928 M | 941 M | 846 M | 1.3 B | 1.6 B | 1.4 B | 1.5 B | 1.5 B | 1.7 B | 1.1 B |
| WAZ | 544.1 M | 544.1 M | 544.1 M | 544.1 M | 544.1 M | 578.2 M | 627.9 M | 673 M | 739.3 M | 708.5 M | 653.6 M | 826.9 M | 883.2 M | 817.7 M | 837.9 M | 963.6 M | 789 M |
| PHI1 | 679 M | 679 M | 679 M | 679 M | 679 M | 546 M | 1.9 B | 1.5 B | 1.6 B | 1.6 B | 1.5 B | 505 M | (171 M) | (168 M) | 513 M | 461.7 M | 737.3 M |
Spermosens AB and related stocks such as WuXi AppTec, Thermo Fisher Scientific, and Danaher Operating Income description
Operating Income is the amount of profit realized from Spermosens AB operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Spermosens AB is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Spermosens AB | 9R5 |
Specialization | Healthcare, Diagnostics & Research |
| Business Address | Medicon Village, Lund, |
| Exchange | Frankfurt Exchange |
null 0.0014
Other Information on Investing in Spermosens Stock
Spermosens financial ratios help investors to determine whether Spermosens Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spermosens with respect to the benefits of owning Spermosens security.